Industry
Biotechnology
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Loading...
Open
18.08
Mkt cap
13B
Volume
1.4M
High
18.57
P/E Ratio
-81.05
52-wk high
33.89
Low
17.80
Div yield
N/A
52-wk low
2.10
Portfolio Pulse from
December 15, 2024 | 12:45 pm
Portfolio Pulse from
December 07, 2024 | 12:30 am
Portfolio Pulse from
December 02, 2024 | 7:30 pm
Portfolio Pulse from
November 30, 2024 | 11:30 am
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 2:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 11:08 am
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 7:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 3:51 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.